MENU

Completion of a Successful Management Buyout Transaction

Nuchem Therapeutics is pleased to announce Senior Management buyout of the company from Amorchem LP, the venture capital fund which founded NuChem in 2011.

Senior management of the company, comprised of Marc LeBel, Daniel Guay, Marc Janes and John Mancuso, acquired 95% of the voting shares from Amorchem LP, the venture capital fund which founded NuChem in 2011. “The present economic situation allows us to forecast strong growth at NuChem over the next few years. Our success is propelled by the company’s exacting attention to client satisfaction, a highly engaged scientific team and our expansion into a customized and dedicated facility,” says Marc LeBel, President. “The team greatly appreciates the openness with which AmorChem approached the MBO, as well as the opportunity the fund offered to us with the original starting up of NuChem,” continues Daniel Guay, Chief Scientific Officer.

The transaction was made possible by the financial support of Investissement Québec (IQ) and Fonds de Transfert d’Entreprises du Québec. The IQ team quickly understood and adapted to the particularities of the transaction, making IQ a natural partner.